Diversified Healthcare Trust (DHC)
NASDAQReal EstateReit - Healthcare FacilitiesSnapshot 2026-09-04
$7.51-2.09%
Close 2026-09-04 · 1-day change
NASDAQReal EstateReit - Healthcare FacilitiesSnapshot 2026-09-04
Intact: The reason to own it still holds.
DHC raised its 2026 EBITDA guidance to $300M-$315M. Revenue is expected near $1.5 billion in 2026. The company keeps its dividend at $0.01 per share. Recent earnings beats show some operational improvement.
DHC is still losing money with negative EPS expected through 2027. Net income declined from -$21M to -$43M recently. Capital spending cuts may limit growth. The turnaround progress is slow and uncertain.
The market expects about 4% revenue growth. Our fair value is much higher than the Street's median target. We see upside if DHC improves profitability and EBITDA as guided.
Breaks if: Adjusted EBITDAre falls below $290 million in FY26
Breaks if: Dividend per share falls below $0.01 in FY26
Breaks if: Recurring CapEx exceeds $115 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround situation in the real estate sector. The current thesis state is cautious, as recent financial performance has been weak, but management is stable and focused on improving guidance.
The market seems to have priced in a low expectations gap, indicating that DHC is viewed as cheap compared to its peers. However, the valuation reflects a justified stance, suggesting that investors are aware of the company's challenges.
Fundamentals may remain weak in the near term, given the company's loss-making status and recent financial performance. However, management's commitment to improving guidance and maintaining dividends could support stability.
The future performance of DHC hinges on several factors, including potential changes in Federal Reserve interest rates and the performance of sector peers. Additionally, any cuts in guidance could negatively impact sentiment.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management has set a guidance for total recurring CapEx between $100M and $115M for 2026.
Breaks if: Revenue falls below $1.4 billion in FY26
Over the next 1 to 3 years, DHC's outlook will depend on management's ability to improve financial guidance and navigate sector headwinds. Not investment advice.